Cytogen Corporation (Nasdaq: CYTO) has recently been issued United States patent number 7,135,457 covering its oral drug delivery agents: random peptide compositions that bind to gastro-intestinal tract (GIT) transport receptors.
The particular patent (United States patent number 7,135,457) covers compositions of Cytogen's oral delivery agents that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tract (GIT), and derivatives and analogs thereof, and nucleotide sequences coding for said proteins and derivatives.
The oral delivery agents are useful in facilitating the transport of active agents from the lumenal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT.
Find more details from the press release.
Comment Preview